ASA rules against supreme CBD for misleading digital ad suggesting CBD as an alternative to antidepressants and medical treatment.

Supreme CBD, located in Liverpool, has recently received criticism from the Advertising Standards Authority (ASA) for its marketing material. The firm had to deal with two similar decisions in November and February of last year. Concerning cannabidiol (CBD), which were both supported.

The company, which is founded by former British professional boxer Antony Fowler, highlighted them in an Instagram post. On May 9 of this year, Fowler posted a video of two people on his account. And one individual stated that Supreme CBD is still questioned. Then you see a doctor and are prescribed antidepressants; they suggest you take these medications. The way antidepressants operate is by balancing hormones in the body through the immune system, which is a part of your end cannabinoid system.

Another person replied, I can't mention on you taking antidepressants, but I wouldn't suggest antidepressants at all. I'd suggest getting off of them, and I'd suggest CBD. Also, I understand that this appears somewhat like an advertisement, but it was beneficial to me.

According to the ASA, the CAP Code stated that advertisers are not allowed to recommend necessary treatment for conditions for which medical care should be provided. Also, advertisers are not allowed to provide specific advice regarding the diagnosis or healthcare of such conditions unless such advice, diagnosis, or treatment was carried out under the guidance of a qualified medical expert.

Depression and chronic anxiety were disorders that required medical treatment. Any advice or treatment related to those disorders should have been provided under the proper guidance, regardless of any data supporting CBD's benefit. Although they valued Supreme CBD's guarantee that the advertisement had been taken down, they did not receive evidence to show that their product and recommendations were supplied under the guidance of a qualified specialist.

The regulator requested Supreme CBD Ltd t/a SupremeCBD to make sure that future ads did not state or suggest that their products could prevent, treat, or cure chronic depression or anxiety and failed to discourage treatment for disorders for which medical care should be needed. They also required that the advertisement not appear again in its current form.